Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $203.18 | 10 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $64.02 | 4 | $0 (2023) |
| Novo Nordisk Inc | $63.86 | 4 | $0 (2023) |
| Lilly USA, LLC | $59.81 | 1 | $0 (2022) |
| GlaxoSmithKline, LLC. | $15.49 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $37.91 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($19.20) |
| 2022 | $165.27 | 8 | Lilly USA, LLC ($59.81) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/28/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Diabetes | ||||||
| 01/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: DIABETES | ||||||
| 12/02/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: DIABETES | ||||||
| 10/20/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Diabetes | ||||||
| 10/15/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $59.81 | General |
| Category: Diabetes | ||||||
| 10/06/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: DIABETES | ||||||
| 07/27/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: DIABETES | ||||||
| 07/13/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.09 | General |
| Category: Diabetes | ||||||
| 06/23/2022 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BEXSERO, PEDIARIX | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: VACCINES | ||||||
| 01/24/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 303 | 389 | $51,424 | $9,827 |
| 2022 | 36 | 2,413 | 3,526 | $338,890 | $73,374 |
| 2021 | 23 | 872 | 1,046 | $102,898 | $26,434 |
| 2020 | 2 | 34 | 40 | $4,264 | $169.52 |
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 81 | $14,422 | $2,962 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 51 | $9,843 | $1,866 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 20 | 26 | $7,158 | $1,794 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 21 | 25 | $4,650 | $1,433 | 30.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 46 | 60 | $1,320 | $453.60 | 34.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 18 | 20 | $3,260 | $301.20 | 9.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 15 | 15 | $1,260 | $246.90 | 19.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 21 | 22 | $4,312 | $212.00 | 4.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 24 | 32 | $2,336 | $201.53 | 8.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 15 | 15 | $1,515 | $190.00 | 12.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 15 | 16 | $1,088 | $152.32 | 14.0% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 13 | 26 | $260.00 | $14.64 | 5.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 199 | 315 | $56,070 | $15,959 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 180 | 249 | $48,057 | $15,348 | 31.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 87 | 99 | $5,445 | $4,969 | 91.3% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2022 | 11 | 11 | $3,014 | $2,772 | 92.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 42 | 42 | $2,790 | $2,734 | 98.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 205 | 257 | $50,372 | $2,528 | 5.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2022 | 121 | 151 | $12,684 | $2,432 | 19.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 65 | 73 | $11,899 | $2,395 | 20.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 218 | 310 | $22,630 | $2,175 | 9.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 85 | 117 | $17,316 | $2,002 | 11.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 18 | $3,744 | $1,943 | 51.9% |
| 82306 | Vitamin d-3 level | Office | 2022 | 64 | 68 | $13,532 | $1,929 | 14.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 90 | 90 | $1,890 | $1,852 | 98.0% |
About Ruby Ayres
Ruby Ayres is a Family healthcare provider based in Bethel, Alaska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2019. The National Provider Identifier (NPI) number assigned to this provider is 1801369921.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ruby Ayres has received a total of $203.18 in payments from pharmaceutical and medical device companies, with $37.91 received in 2023. These payments were reported across 10 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($203.18).
As a Medicare-enrolled provider, Ayres has provided services to 3,622 Medicare beneficiaries, totaling 5,001 services with total Medicare billing of $109,805. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Practice Information
- Specialty Family
- Other Specialties Family, Family
- Location Bethel, AK
- Active Since 01/11/2019
- Last Updated 02/28/2025
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1801369921
Products in Payments
- JARDIANCE (Drug) $64.02
- MOUNJARO (Drug) $59.81
- Ozempic (Drug) $51.77
- SHINGRIX (Biological) $15.49
- Rybelsus (Drug) $12.09
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Bethel
Mary Galasinski, Aprn, APRN
Family — Payments: $1,331
Abby Pritchard, Aprn, APRN
Family — Payments: $352.47
Kathy Brock, Fnp-Bc, FNP-BC
Family — Payments: $323.38
Kristin Arsenault
Family — Payments: $193.28
Christopher Pioli
Family — Payments: $130.53
Christine Seidell, Aprn, APRN
Family — Payments: $105.45